| First Author | Schneider C | Year | 2016 |
| Journal | Blood | Volume | 128 |
| Issue | 5 | Pages | 660-6 |
| PubMed ID | 27166359 | Mgi Jnum | J:236059 |
| Mgi Id | MGI:5804513 | Doi | 10.1182/blood-2015-11-684357 |
| Citation | Schneider C, et al. (2016) FBXO11 inactivation leads to abnormal germinal-center formation and lymphoproliferative disease. Blood 128(5):660-6 |
| abstractText | The BCL6 proto-oncogene encodes a transcriptional repressor that is required for the germinal center (GC) reaction and is implicated in lymphomagenesis. BCL6 protein stability is regulated by F-box protein 11 (FBXO11)-mediated ubiquitination and degradation, which is impaired in approximately 6% of diffuse large B-cell lymphomas that carry inactivating genetic alterations targeting the FBXO11 gene. In order to investigate the role of FBXO11 in vivo, we analyzed GC-specific FBXO11 knockout mice. FBXO11 reduction or loss led to an increased number of GC B cells, to an altered ratio of GC dark zone to light zone cells, and to higher levels of BCL6 protein in GC B cells. B-cell receptor-mediated degradation of BCL6 was reduced in the absence of FBXO11, suggesting that FBXO11 contributes to the physiologic downregulation of BCL6 at the end of the GC reaction. Finally, FBXO11 inactivation was associated with the development of lymphoproliferative disorders in mice. |
